Get the Stockscreener App
195.15
6.14%
11.29
After Hours:
195.21
0.06
+0.03%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $195.15, with a volume of 2.37M.
It is up +6.14% in the last 24 hours and up +9.97% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$183.86
Open:
$189.52
24h Volume:
2.37M
Relative Volume:
1.19
Market Cap:
$302.65B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
58.61
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+5.10%
1M Performance:
+9.97%
6M Performance:
+113.12%
1Y Performance:
+174.36%
1-Day Range:
$189.17
$196.41
1-Week Range:
$183.49
$196.41
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
195.15 | 294.07B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,213.91 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.04 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
261.07 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.56 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.90 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug - marketscreener.com
Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Th - GuruFocus
Abbisko teams with AstraZeneca on lung cancer trial after China IND clearance - Stock Titan
Why Astrazeneca (AZN) Dipped More Than Broader Market Today - Yahoo Finance
AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Te - GuruFocus
AstraZeneca PLC Stock (AZN) Moved Down by 3.02% on Jul 1: What Investors Need To Know - TradingKey
AstraZeneca plc focuses on long-term growth as global pipeline expands - AD HOC NEWS
AstraZeneca admits 14,784 shares to London Stock Exchange - Investing.com
AstraZeneca PLC outlines long-term growth strategy as global drug portfolio expands - AD HOC NEWS
AstraZeneca admits 14,784 shares to London Stock Exchange By Investing.com - Investing.com Canada
AstraZeneca (NYSE: AZN) adds 14,784 employee scheme shares - Stock Titan
AstraZeneca (AZN) reports 1.55B total voting rights as of June 2026 - Stock Titan
REGAstraZeneca PLCAdmission of Further Securities to Trading - TradingView
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised) - TradingView
ASTRAZENECA : Goldman Sachs reaffirms its Buy rating - marketscreener.com
BofA Forecasts In-line Q2 Sales, EPS for AstraZeneca; Buy Rating Maintained - marketscreener.com
Price to earnings forward of AstraZeneca PLC – SWB:ZEG - TradingView
ETFs Investing in AstraZeneca PLC Stocks - TradingView
AstraZeneca slides Tuesday, underperforms market - MarketWatch
AstraZenecaEnhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours - marketscreener.com
AstraZeneca PLC strengthened by Enhertu EU approval. JP Morgan reiterates buy rating on the stock - AD HOC NEWS
ASTRAZENECA : Sell rating from Deutsche Bank - marketscreener.com
RB Capital Management, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com
AstraZeneca To Pay $34M In Texas Kickbacks Settlement - Law360
AstraZeneca Details Bone Health Data For Strensiq Successor - insights.citeline.com
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe - Benzinga
Astrazeneca plc Datroway Recommends for Approval in EU for TNBC - marketscreener.com
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors - TradingView
EU clears AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu for HER2+ solid tumours - Stock Titan
AstraZeneca, Daiichi Sankyo Win EU Approval for Enhertu in HER2-positive Solid Tumors - marketscreener.com
AstraZeneca's Datroway and Enhertu candidates receive EU approval - Sharecast.com
AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC - DirectorsTalk Interviews
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours - AstraZeneca
AstraZeneca’s Datroway gets EU panel backing for breast cancer By Investing.com - Investing.com UK
AZN Stock Quote Price and Forecast - CNN
Price to sales forward of AstraZeneca PLC – LSE:AZN - TradingView
AstraZeneca PLC AZN Q3 2025 Earnings Call Dallas Cowboys Schedule 2026 (4z9l16BTZU) - Mshale
Price to sales forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView
AstraZeneca highlights long-term oncology pipeline, shares supported by solid S&P 500 presence - Ad-hoc-news.de
AstraZeneca focuses on long-term oncology strategy, shares anchored in the FTSE 100 - Ad-hoc-news.de
The Breztri Aerosphere from AstraZeneca plctriple therapy aims at severe COPD - Ad-hoc-news.de
AstraZeneca cautious after EU panel vote, shares reflect Tavneos setback - Ad-hoc-news.de
AstraZeneca climbs Friday, outperforms market - MarketWatch
Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI
Could This Clinical Milestone Reshape AstraZeneca’s (LSE:AZN) Future? - Kalkine Media
Daiichi Sankyo and AstraZeneca Announce Datroway Recommends for Approval in EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy - marketscreener.com
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout - Yahoo Finance
AstraZeneca updates on pipeline and AI efforts, shares tracked by analysts - Ad-hoc-news.de
AstraZeneca's, Daiichi's Datroway recommended for further EU approval - London South East
AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy - marketscreener.com
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):